Grifols SA

Grifols, S.A. announced changes to its Board of Directors following an extraordinary meeting on June 19, 2026. Ms. Enriqueta Felip Font resigned from her position as a board member and from the Sustainability, Communication and Reputation Committee for professional reasons. The Board unanimously appointed Ms. Ester Masllorens Llinàs as a new independent director and Mr. Pascal Ravery as a new member of the Sustainability, Communication and Reputation Committee.

Grifols' Ordinary General Shareholders' Meeting approved a preferred dividend of EUR 0.01 per Class B Share and an ordinary dividend of EUR 56,065,663 against fiscal year 2025 results, both payable on July 2, 2026. The meeting also authorized a share capital reduction of up to 10% by redeeming treasury shares and re-elected Montserrat Muñoz Abellana and Susana González Rodríguez to the Board of Directors for four-year terms. Additionally, Deloitte Auditores, S.L. was re-elected as the statutory auditor for fiscal years 2027-2029, and the Board was granted authority for future capital increases and treasury stock acquisitions.

Grifols announced the U.S. launch of FESILTY, a new fibrinogen concentrate, now available for treating acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency (CFD). Approved by the U.S. FDA in December, FESILTY expands Grifols' bleeding management portfolio by offering a highly purified product that enables rapid and predictable restoration of fibrinogen levels. This new treatment option provides healthcare professionals with a safe, effective, and reliable solution for a rare inherited condition.

Grifols SA has called an Ordinary General Shareholders' Meeting for June 17 or 18, 2026, to address several key corporate matters. The agenda includes the approval of 2025 financial results, re-election of auditors and directors, and amendments to the directors' remuneration policy. Significantly, shareholders will vote on authorizing the Board to increase share capital by up to 50% and to reduce share capital by up to 10% through treasury share redemption. Additionally, the meeting will consider renewing the delegation for the listing of Class A shares on NASDAQ.

Grifols reported Q1 2026 revenue of €1,700 million, a 3.3% increase at constant currency, driven by strong Biopharma growth (+6.8% cc). Adjusted EBITDA reached €381 million, up 0.8% cc, with a stable margin of 22.4%. Group profit increased 21.9% year-on-year to €73 million, and free cash flow pre-M&A improved by €30 million. The company successfully refinanced all 2027 debt maturities, strengthening its balance sheet and financial flexibility, and saw multiple credit rating upgrades. Strategic initiatives like the Egypt self-sufficiency project are advancing, and Grifols is evaluating a potential IPO of its U.S. Biopharma business.